Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users

Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie—thanks to Nurtec ODT's dual acute-plus-prevention nod and an aggressive digital-first strategy.

Digital ads across social media roll up Nurtec's double indication into one message—the same dose can treat acute migraine and prevent the next one.